Can failure be predicted in methotrexate treatment with the modified parameter?

Basit Öğe Kaydı
dc.contributor.authorBaskiran, Yusuf
dc.contributor.authorUckan, Kazim
dc.contributor.authorCelegen, Izzet
dc.date.accessioned2024-05-19T14:41:07Z
dc.date.available2024-05-19T14:41:07Z
dc.date.issued2024
dc.departmentİstinye Üniversitesien_US
dc.description.abstractObjective The objective of the study was to increase the prediction of success of single-dose methotrexate therapy in ectopic pregnancy patients with modified parameters obtained from complete blood count and beta-human chorionic gonadotropin (beta-hCG) parameters. In this way, it was aimed to predict patients whose methotrexate treatment may fail and rupture, to avoid unnecessary methotrexate treatment, to shorten the duration of hospital stay and to reduce patient mortality. Materials and methods 233 patients diagnosed with ectopic pregnancy between January 1, 2017, and March 01, 2022, in the obstetrics and gynecology service of a tertiary center were included in the study. Results The mean of beta-hCG was 1976 in the methotrexate group and 2358 in the surgery group (p < 0.05). The ROC curve determined the effect of BW (beta-hCGxWBC/1000) and BP (beta-hCGx1000/PLT) markers in diagnosing patients who will need surgery in ectopic pregnancy. The areas under the ROC curve for beta-hCG, BW and BP were 0.86, 0.99 and 0.94, respectively (p < 0.05). beta-hCG > 2139.03, BW > 30.96 and BP > 10.17 values were significantly associated with the need for surgery in ectopic pregnancy patients (p < 0.05). Logistic regression analysis revealed that a 1-unit increase in BP caused a statistically significant 1.77-fold increase in surgical need in patients with ectopic pregnancy. In contrast, a 1-unit increase in BW caused a 2.34-fold increase in surgical need (p < 0.05). Conclusion The study results showed that BW and BP values together with beta-hCG are effective in predicting ectopic pregnancy patients who may undergo surgery.en_US
dc.identifier.doi10.1007/s00404-024-07433-1
dc.identifier.issn0932-0067
dc.identifier.issn1432-0711
dc.identifier.pmid38714561en_US
dc.identifier.scopus2-s2.0-85192263686en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org10.1007/s00404-024-07433-1
dc.identifier.urihttps://hdl.handle.net/20.500.12713/5064
dc.identifier.wosWOS:001215556400004en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherSpringer Heidelbergen_US
dc.relation.ispartofArchives of Gynecology and Obstetricsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmz20240519_kaen_US
dc.subjectEctopic Pregnancyen_US
dc.subjectMethotrexateen_US
dc.subjectInflammationen_US
dc.subjectBeta-Hcgen_US
dc.titleCan failure be predicted in methotrexate treatment with the modified parameter?en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu